So that's where she's gone...

Posted 13 June 2024 AM

Astellas Australia has appointed Nirelle Tolstoshev to the role of General Manager, ending speculation on who would take the role and Tolstoshev's next move after Organon announced on Sunday that she was leaving the company.

It's a perfect fit with Tolstoshev who brings her deep experience in both oncology and women's health to Astellas which is rolling out its game-changing drug to prevent menopausal hot flushes, Veoza, approved by the TGA in March. Analysts have pegged it as a blockbuster, expected to bring in US$1.9 billion globally by 2028. The company also has a strong presence locally in oncology with big name cancer drugs Xtandi and Padcev. 

To see the whole article, please login